Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Moat Score: 0/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADX:JULPHAR Gulf Pharmaceutical Industries PSC ADX:JULPHAR
54 GF Score
Price د.إ1.04
GF Value د.إ1.08
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gulf Pharmaceutical Industries PSC Moat Score?

Gulf Pharmaceutical Industries PSC has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Gulf Pharmaceutical Industries PSC has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Gulf Pharmaceutical Industries PSC might have No Moat - No discernible moat.

Gulf Pharmaceutical Industries PSC  (ADX:JULPHAR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Gulf Pharmaceutical Industries PSC Moat Score Related Terms

ADX:JULPHAR
54GF Score
Gulf Pharmaceutical Industries PSC ADX:JULPHAR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued. The current stock price of د.إ1.04 is trading 3.7% below its estimated GF Value™ of د.إ1.08. GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.

Key valuation signals for ADX:JULPHAR:

  • Moat Score: 0
  • GF Value™: د.إ1.08 vs. price of د.إ1.04 (3.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gulf Pharmaceutical Industries PSC Business Description

Address Airport Road, P.O. Box 997, Digdaga, Ras Al Khaimah, ARE
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score

Get the complete analysis for ADX:JULPHAR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

د.إ1.04
Price
د.إ1.08
GF Value